An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot. But as scrutiny builds around the crucial mRNA technology,

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week.